Fractyl's Revita meets 6-month endpoint in REMAIN-1 pivotal study
Fractyl Health announced topline 6-month data showing Revita maintained 80% of GLP-1 induced weight loss versus 67% in sham controls. This neuroendocrine intervention offers a new therapeutic option in the weight maintenance market following GLP-1 discontinuation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed